Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioventus ( (BVS) ) just unveiled an announcement.
On July 31, 2025, Bioventus LLC entered into a $400 million credit agreement with Wells Fargo Bank and other financial institutions. The agreement includes a $100 million revolving credit facility and a $300 million term loan, which will be used to refinance existing credit facilities. The credit facilities, secured by the company’s assets, will mature in 2030 and include various financial covenants and interest rates adjusted based on the company’s leverage ratio. This strategic financial move is expected to strengthen Bioventus’s financial position and operational flexibility.
The most recent analyst rating on (BVS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.
Spark’s Take on BVS Stock
According to Spark, TipRanks’ AI Analyst, BVS is a Neutral.
Bioventus’s stock score is primarily influenced by its current financial struggles, with high leverage and declining revenue posing significant risks. However, positive corporate events such as FDA clearances and strategic growth initiatives, along with a neutral technical outlook, moderately offset these concerns.
To see Spark’s full report on BVS stock, click here.
More about Bioventus
Bioventus LLC is a subsidiary of Bioventus Inc., operating in the healthcare industry. The company focuses on developing and providing medical devices and products, particularly in the field of orthobiologics, which are used to enhance the body’s natural healing processes.
Average Trading Volume: 454,095
Technical Sentiment Signal: Sell
Current Market Cap: $507.7M
Find detailed analytics on BVS stock on TipRanks’ Stock Analysis page.